Global Injectable IVF Medications Supply, Demand and Key Producers, 2024-2030

Global Injectable IVF Medications Supply, Demand and Key Producers, 2024-2030

The global Injectable IVF Medications market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The fertility preservation and infertility treatment market has witnessed significant growth in recent years, driven by factors such as increasing infertility rates, delayed pregnancies, advancements in assisted reproductive technologies (ART), and growing awareness. Fertility preservation technologies, including egg freezing and sperm banking, have gained popularity among individuals seeking to preserve their reproductive potential. In the infertility treatment segment, in vitro fertilization (IVF), intrauterine insemination (IUI), and other ART procedures have become mainstream options. Future developments are anticipated in areas such as personalized medicine, gene editing technologies, and improved success rates in ART procedures. The market is likely to see ongoing advancements, innovations, and collaborations aimed at addressing infertility challenges and expanding the range of options available to individuals and couples.

Injectable IVF (In Vitro Fertilization) medications are pharmaceutical drugs administered via injection to stimulate and regulate a woman's reproductive system during the fertility treatment process. These medications typically include hormones such as gonadotropins and follicle-stimulating hormone (FSH), which encourage the development of multiple eggs within the ovaries. Additionally, other drugs like human chorionic gonadotropin (hCG) are used to trigger the final maturation of eggs before retrieval. Injectable IVF medications play a crucial role in controlling the ovulation process, optimizing egg production, and enhancing the chances of successful fertilization during assisted reproductive technologies.

This report studies the global Injectable IVF Medications production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Injectable IVF Medications, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Injectable IVF Medications that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Injectable IVF Medications total production and demand, 2019-2030, (K Units)

Global Injectable IVF Medications total production value, 2019-2030, (USD Million)

Global Injectable IVF Medications production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Injectable IVF Medications consumption by region & country, CAGR, 2019-2030 & (K Units)

U.S. VS China: Injectable IVF Medications domestic production, consumption, key domestic manufacturers and share

Global Injectable IVF Medications production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)

Global Injectable IVF Medications production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Injectable IVF Medications production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Injectable IVF Medications market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gonal-F (Merck), Follistim (Organon), Bravelle (Ferring), Menopur (Ferring), Fostimon (IBSA), Puregon (Organon), BEMFOLA (Gedeon Richter), Novarel (Ferring) and Ovidrel (Merck), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Injectable IVF Medications market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Injectable IVF Medications Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Injectable IVF Medications Market, Segmentation by Type
Follicle Stimulating Hormone (FSH)
Luteinizing Hormone (LH)
Human Chorionic Gonadotropin (hCG)
Others

Global Injectable IVF Medications Market, Segmentation by Application
IVF and Embryo Transfer
Infertility Treatment

Companies Profiled:
Gonal-F (Merck)
Follistim (Organon)
Bravelle (Ferring)
Menopur (Ferring)
Fostimon (IBSA)
Puregon (Organon)
BEMFOLA (Gedeon Richter)
Novarel (Ferring)
Ovidrel (Merck)
Synarel (Pfizer Medical)
Follitrope (LG Chem)
Profasi (Serum Institute Of India)
Livzon
GenSci

Key Questions Answered

1. How big is the global Injectable IVF Medications market?

2. What is the demand of the global Injectable IVF Medications market?

3. What is the year over year growth of the global Injectable IVF Medications market?

4. What is the production and production value of the global Injectable IVF Medications market?

5. Who are the key producers in the global Injectable IVF Medications market?